Pharmaceuticals, Biotechnology & Life Sciences

IQVIA’s July 2026 insider filings reveal routine, rule‑compliant equity purchases and a large director‑officer acquisition—showing strong liquidity management and regulatory transparency.

AbbVie beats earnings thanks to a surge in Skyrizi sales, but a costly Apogee acquisition forces a profit forecast cut, sparking investor worry about short‑term earnings drag.

MERCK KGAA beats earnings estimates yet faces tech‑driven valuation pressure, as investors weigh its oncology, immunology, and COVID‑19 pipeline amid semiconductor market shifts.

Explore how Pfizer’s latest earnings, patent cliffs, and biosimilar strategy shape its growth outlook in today’s pharma market.

Novo Nordisk’s failed cardiovascular Phase‑III trial reveals platform risks, regulatory shifts, and new digital‑health, gene‑editing opportunities to drive future growth.

Haleon plc’s July 30 2026 filing confirms consistent U.S. reporting, steady H1 revenue, and a focused consumer‑health strategy that balances patent protection, M&A opportunities, and disciplined R&D to sustain growth.

Neurocrine Biosciences’ Q2 2026 shows 21.6% revenue growth, driven by INGREZZA and VYKAT XR, with strong EPS, margins, and a new $4.3 B revenue outlook.

AbbVie’s Q2 2026 earnings beat on Skyrizi and Rinvoq growth, yet its $5.3 billion Apogee deal trims EPS – a nuanced look at gains, integration costs and future upside.

See how Bayer’s stock rose after the US Supreme Court glyphosate ruling, its pharma focus, and a promising Asundexian stroke‑risk study.

Merck KGaA’s Q2 2026 earnings show steady growth, strong oncology and cardiovascular sales, and a robust pipeline moving into regulatory review amid supply‑chain uncertainty.